Sigyn Therapeutics, Inc. Overview
Pro stress-test →Sigyn Therapeutics is a San Diego-based development-stage medical technology company developing dialysis-like blood purification therapies for severe disease. The lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company trades on the OTC market under ticker SIGY with a micro-cap valuation.
Strategic Profile
Pro stress-test →Sigyn's development decisions are guided by two main prerequisites: that a candidate therapy should address a clearly defined limitation in healthcare, and that successful clinical advancement could establish a potential competitive advantage relative to established therapeutic approaches. The company is a developer of dialysis-like therapies to address cardiovascular disease and cancer. The company is exploring strategic alternatives including potential merger and asset sale initiatives as of (March 2026).
Competitive Landscape
Pro stress-test →Sigyn operates in the dialysis-inspired blood purification and extracorporeal therapy space. While direct competitors are limited due to the novel mechanism, the company faces indirect competition from established therapeutic approaches for sepsis (antibiotics, vasopressors), cardiovascular disease (statins, other drug classes), and cancer treatments (chemotherapy, immunotherapy). The company's focus on addressing pathogen-associated conditions and inflammatory disorders positions it against both pharmaceutical and medical device incumbents.
Industry Context
Sigyn Therapeutics, Inc. operates in Extracorporeal blood purification devices.
Key facts
Headquarters: San Diego, CA · Market cap: $6.4M